8-K: Neuronetics Achieves Record Revenue in Q4 and Full Year 2023, Driven by Treatment Session Growth

Neuronetics reported record fourth-quarter and full-year 2023 financial results, highlighted by a 12% increase in Q4 revenue and positive cash flow.

Summary

• Neuronetics announced its financial results for the fourth quarter and full year of 2023, achieving record revenue for both periods.
• Fourth-quarter revenue reached $20.3 million, a 12% increase compared to the same period in 2022.
• Full-year revenue for 2023 totaled $71.3 million, a 9% increase year-over-year.
• The company saw a significant increase in U.S. treatment session revenue, which grew by 20% in Q4 and 13% for the full year.
• Neuronetics achieved positive cash flow of approximately $1.5 million in the fourth quarter, ending the year with $60 million in cash and cash equivalents.
• The company's net loss improved to $(5.4) million in Q4 2023, compared to $(8.3) million in Q4 2022, and $(30.2) million for the full year 2023, compared to $(37.2) million in 2022.
• EBITDA for Q4 2023 was $(3.0) million, an improvement from $(6.5) million in Q4 2022, and $(22.8) million for the full year 2023, compared to $(31.3) million in 2022.
• The company launched the first cohort of its Better Me Guarantee Provider pilot program in January 2024, with plans to expand the program in April 2024.
• Several healthcare policies were updated to reduce the number of required antidepressant medication attempts before TMS treatment eligibility, from four to two.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with record revenue, improved profitability, and positive cash flow. The company is also expanding its programs and seeing increased adoption of its technology. However, there are some risks and challenges that need to be monitored.

Positives

• The company achieved record revenue for both the fourth quarter and full year of 2023.
• U.S. treatment session revenue showed strong growth, indicating increased utilization of the NeuroStar system.
• Neuronetics generated positive cash flow in the fourth quarter, a significant milestone for the company.
• The company's net loss and EBITDA improved compared to the previous year.
• Healthcare policy updates are reducing barriers to TMS treatment, potentially increasing patient access.
• The Better Me Guarantee Provider pilot program is expanding, which could further drive treatment utilization.
• Operating expenses decreased in both the fourth quarter and full year of 2023.

Negatives

• International revenue decreased by 35% in the fourth quarter of 2023.
• Full-year gross margin decreased by 380 basis points, primarily due to an inventory impairment and one-time expenses.
• Cash and cash equivalents decreased from $70.3 million at the end of 2022 to $59.7 million at the end of 2023.
• U.S. NeuroStar Advanced Therapy system revenue decreased by 2% in Q4 and 1% for the full year.

Risks

• The company's ability to achieve or sustain profitable operations is uncertain due to its history of losses.
• Neuronetics relies heavily on the sale and use of its NeuroStar Advanced Therapy system to generate revenue.
• The company faces risks related to competition, product defects, and intellectual property protection.
• The company's ability to successfully roll out the Better Me Guarantee Provider Program on the planned timeline is not guaranteed.
• The company's self-sustainability and existing cash balances are subject to risks.
• The company's ability to achieve cash flow break-even on a full-year basis in 2025 is not guaranteed.

Future Outlook

The company expects total worldwide revenue between $16.7 million and $17.7 million for the first quarter of 2024, and between $78.0 million and $80.0 million for the full year 2024. Total operating expenses are expected to be between $80.0 million and $84.0 million for the full year 2024.

Management Comments

• We wrapped up an exciting 2023 with a strong fourth quarter.
• We continued to see improving utilization trends coming as a direct results of the many educational and training initiatives we have instituted over the past 18 months.
• Importantly, the utilization within our local consumable customers grew by over 20% in the quarter, and we saw improving performance at Greenbrook sites.
• We are very excited about 2024.
• We believe the rigiourous set of standards that BMGP participants agree to will help these sites identify more patients in need, who can ultimately benefit from treatment using NeuroStar.

Industry Context

The announcement reflects a growing trend in the medical technology sector towards non-invasive treatments for mental health conditions. The policy updates from major healthcare providers indicate increasing acceptance and coverage for TMS therapy, which could benefit Neuronetics and its competitors.

Comparison to Industry Standards

• Neuronetics' revenue growth of 12% in Q4 and 9% for the full year is a positive sign, indicating strong demand for their NeuroStar system. Comparatively, companies like Magstim and Brainsway, which also offer TMS devices, have shown similar growth trends in recent years, although specific financial details are not always directly comparable due to differences in reporting and business models.
• The increase in treatment session revenue is a key indicator of the company's success in driving utilization of its technology. This metric is crucial for medical device companies, as it demonstrates the adoption and effectiveness of their products in clinical practice. Companies like Medtronic, while operating in a broader medical device space, also focus on increasing utilization of their products through various programs and initiatives.
• The achievement of positive cash flow in Q4 is a significant milestone for Neuronetics, as many medical technology companies, especially those in the growth phase, often struggle with profitability. This achievement puts Neuronetics in a stronger position compared to some of its peers that are still burning cash.
• The gross margin of 77.6% in Q4 is relatively high for a medical device company, indicating strong pricing power and efficient cost management. However, the full-year gross margin of 72.5% was impacted by one-time expenses, highlighting the importance of consistent operational performance. Companies like Intuitive Surgical, known for their high-margin robotic surgery systems, often serve as benchmarks for gross margin performance in the medical device industry.

Stakeholder Impact

• Shareholders will likely view the record revenue and positive cash flow as positive developments.
• Employees may be encouraged by the company's growth and improved financial performance.
• Customers (healthcare providers) may benefit from the expanded Better Me Guarantee Provider program and increased patient access to TMS therapy.
• Patients will benefit from increased access to TMS therapy due to policy updates and the Better Me Guarantee Provider program.
• Suppliers may see increased demand for components and materials due to the company's growth.

Next Steps

• The company plans to continue the measured roll-out of the Better Me Guarantee Provider program, with new providers slated for inclusion in April 2024 and other dates during the year.
• Neuronetics will host a conference call on March 5, 2024, to discuss the financial results.

Key Dates

Keywords

Neuronetics, NeuroStar, TMS, Transcranial Magnetic Stimulation, Mental Health, Depression, Treatment Session, Revenue, EBITDA, Financial Results, Medical Technology